Crizotinib, an orally bioavailable agent, belongs to the class of c-met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors with potential antineoplastic activity.

877399-53-6

C23H26Cl2FN5O3

510.39

PF2341066;PF-2341066;PF-02341066;PF 02341066;PF02341066;Crizotinib acetate

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years